Van Andel Institute vai.org


Public list: BIO 2016 (619) Pharma Startups (4732) Cancer Therapeutics (1137)

VARi has several research programs in basic sciences that will improve our understanding of the cancer process, including programs rich in functional genomics. They have a long-term commitment to the development of programs that facilitate the translation of these basic science discoveries into therapeutic strategies for attacking cancer and thus improving human health.

VARi has several research programs in basic sciences that will improve our understanding of the cancer process, including programs rich in functional genomics. They have a long-term commitment to the development of programs that facilitate the transl...Show all

Company (Alive / Active)

Phone: 616-234-5000

Fax: 616-234-5001

333 Bostwick NE
Grand Rapids, 49503
Michigan, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Van Andel Institute $18M May 12, 2009
See all 18 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Van Andel Institute Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

NeuroGenomeX

Madison, Wisconsin, United States
Alive / ActiveNeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in...Show allLogin to see details

HTG Molecular Diagnostics

Tucson, Arizona, United States
IPO / Went publicHTG Molecular Diagnostics provides simple, cost effective solutions for accurate RNA testing. In 2013 the company commercialized its Edge instrument platform and a portfolio of mRNA assays that leverage HTG's proprietary nuclease protection chemistry. The capability of the Edge System has been expanded to fully automate sample and targeted library preparation for next-generation sequencing.Login to see details
See all 18 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Highly potent glucocorticoids Sep 25, 2014 May 22, 2018 Patent
Solid forms of curcumin Apr 05, 2012 Sep 20, 2016 Patent
Biomarkers for pancreatic cancer and diagnostic methods Nov 22, 2010 Jan 21, 2014 Patent
Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use Mar 26, 2010 Oct 22, 2013 Patent
Untitled Jun 15, 2006 Jun 18, 2013 Patent
See all 24 patents